PLEASANTON, Calif. (AP) _ 10x Genomics Inc. (TXG) on Wednesday reported a loss of $415.6 million in its fourth quarter.

The Pleasanton, California-based company said it had a loss of $3.87 per share. Losses, adjusted for research and development costs, were 8 cents per share.

The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 28 cents per share.

The life science technology company posted revenue of $112.2 million in the period, also beating Street forecasts. Three analysts surveyed by Zacks expected $101.2 million.

For the year, the company reported that its loss widened to $542.7 million, or $5.37 per share. Revenue was reported as $298.8 million.

10x Genomics shares have risen 32% since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $187.55, more than doubling in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on TXG at https://www.zacks.com/ap/TXG

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News